

UltraSight & Selvas Healthcare to commercialise Al-powered cardiac ultrasound software in Asia

07 February 2024 | News

New joint venture creates pathway for introducing UltraSight's technology to Korean market

Israel-based UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence (AI), has announced a partnership with Selvas Healthcare (subsidiary of Selvas Group), a Korean-based global digital healthcare company with innovative technology in medical device manufacturing and software.

This new joint venture kicks off the introduction of UltraSight's real-time AI guidance technology in Asia, beginning with the regulatory process for approvals that may lead to eventual commercialization and distribution in Korea and the Southeast Asian market.

UltraSight CEO Davidi Vortman said, "We aim to address the significant global disparity between the number of cardiovascular disease patients and the availability of cardiac ultrasound. Having already entered the market in the US, we look forward to embarking on this new venture with SELVAS Healthcare and bringing the benefits of our cardiac imaging technology to Korea, with a long-term vision of expanding UltraSight's footprint throughout Asia."

UltraSight's software pairs with point-of-care ultrasound (POCUS) devices to provide medical professionals with real-time guidance to acquire diagnostic-quality cardiac ultrasound images, regardless of experience level. Selvas Healthcare will have exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea.